Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Longitudinal qPCR monitoring of nucleophosmin 1 mutations after allogeneic hematopoietic stem cell transplantation to predict AML relapse

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1


  1. Campana D, Leung W . Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation. Br J Haematol 2013; 162: 147–161.

    Article  Google Scholar 

  2. Grimwade D, Freeman SD . Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? Blood 2014; 124: 3345–3355.

    CAS  Article  Google Scholar 

  3. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254–266.

    CAS  Article  Google Scholar 

  4. Kronke J, Bullinger L, Teleanu V, Tschurtz F, Gaidzik VI, Kuhn MW et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood 2013; 122: 100–108.

    Article  Google Scholar 

  5. Welch JS . Mutation position within evolutionary subclonal architecture in AML. Semin Hematol 2014; 51: 273–281.

    CAS  Article  Google Scholar 

  6. Kronke J, Schlenk RF, Jensen KO, Tschurtz F, Corbacioglu A, Gaidzik VI et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 2011; 29: 2709–2716.

    Article  Google Scholar 

  7. Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009; 114: 2220–2231.

    CAS  Article  Google Scholar 

  8. Shayegi N, Kramer M, Bornhauser M, Schaich M, Schetelig J, Platzbecker U et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood 2013; 122: 83–92.

    CAS  Article  Google Scholar 

  9. Bacher U, Badbaran A, Fehse B, Zabelina T, Zander AR, Kroger N . Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Exp Hematol 2009; 37: 135–142.

    CAS  Article  Google Scholar 

  10. Ommen HB, Schnittger S, Jovanovic JV, Ommen IB, Hasle H, Ostergaard M et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood 2010; 115: 198–205.

    CAS  Article  Google Scholar 

  11. Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009; 27: 5195–5201.

    CAS  Article  Google Scholar 

  12. Pozzi S, Geroldi S, Tedone E, Luchetti S, Grasso R, Colombo N et al. Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression. Br J Haematol 2013; 160: 503–509.

    Article  Google Scholar 

  13. Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101: 1698–1704.

    CAS  Article  Google Scholar 

  14. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328–333.

    CAS  Article  Google Scholar 

  15. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R . Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA 2014; 111: 2548–2553.

    CAS  Article  Google Scholar 

Download references


This work was supported by the Italian Ministry of Health (RF-2011-02351998), by the Associazione Italiana per la Ricerca sul Cancro (Start-Up Grant #14162), and by the Conquer Cancer Foundation (2014 Young Investigator Award).

Author contributions

EX, FC and LV designed the study and analyzed the data. CT, AC and BM performed the experiments. EX, ES, RG, CM, MGC, MTLS, SM, CC, JP, MB, FC and LV contributed to patient clinical care and data collection. EX, FC and LV wrote the manuscript. All authors have approved the final version of the manuscript.


The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Author information

Authors and Affiliations


Corresponding author

Correspondence to F Ciceri.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Xue, E., Tresoldi, C., Sala, E. et al. Longitudinal qPCR monitoring of nucleophosmin 1 mutations after allogeneic hematopoietic stem cell transplantation to predict AML relapse. Bone Marrow Transplant 51, 466–469 (2016).

Download citation

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links